Although CD19 is important for B-cell biology because of its role in B-cell receptor signaling, several biological and molecular mechanisms have been described as responsible for the appearance of CD19-negative ALL blasts after CART therapy which are ultimately responsible for relapse (Figure 1). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.